Developing a new therapy to replace secretory IgA for patients with Common Variable Immune Deficiency (CVID)
Official title: Preclinical Development of LCTG-001, a Human Secretory IgA Replacement Therapy for CVID Patients
Funded at Lactiga Us INC. · NIH-11067456 · Data updated 2026-11-12
This study is testing a new nasal treatment using a special type of immune protein to help people with Common Variable Immune Deficiency (CVID) fight off infections better, especially in their lungs and nose, where they often get sick.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lactiga Us INC. NIH-funded |
| Lab location | 1 site (North Brunswick, United States) |
| Project start | January 24, 2025 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $304,629 |
| NIH project number | 1R42AI188865-01 |
| Project ID | NIH-11067456 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Common Variable Immune Deficiency, particularly those experiencing recurrent respiratory infections.
✕Less likely to help
Patients who do not have Common Variable Immune Deficiency or those with other types of primary immunodeficiencies may not benefit from this research.
What this research studies
This research focuses on creating a replacement therapy using human secretory IgA for patients suffering from Common Variable Immune Deficiency (CVID). The approach aims to address the limitations of current immunoglobulin replacement therapies, which primarily deliver IgG and do not effectively target the respiratory tract where infections are most common. By developing a therapy that can be administered to the nasal cavity, the research seeks to enhance the immune response in CVID patients, potentially reducing the frequency of infections. The study will involve preclinical testing to evaluate the safety and efficacy of this new treatment.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for CVID patients, potentially reducing their risk of severe infections.
How similar studies have gone: While there have been advancements in immunoglobulin therapies, this specific approach targeting secretory IgA for CVID is novel and has not been extensively tested in prior studies.
Where this research is happening
-
Lactiga Us INC.
North Brunswick, United States Active
Researchers
- Principal investigator: Mane, Viraj Pramod — Lactiga Us INC.
- Study coordinator: Mane, Viraj Pramod
Related research
Other NIH-funded projects on the same topics.
-
Preclinical development of an IgA replacement therapy for CVID patients
A new IgA-dominant nasal therapy is being developed to help people with CVID reduce infections in the airways.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.